Overview of Uriflow (Bethanechol)

Property	Description
Active ingredient	Bethanechol chloride
Form	Tablet, Solution (for injection)
Pharmacological class	Parasympathomimetic agent (Cholinergic Agonist)
General purpose	Restoring proper muscle tone (contractility) to the bladder and gut.
Origin	Synthetic ester

What Type of Medicine is Bethanechol Chloride?

Bethanechol chloride is the active ingredient and is classified as a Cholinergic Muscarinic Agonist, belonging to the larger class of parasympathomimetic agents. This substance is a synthetic ester chemically related to the body's natural neurotransmitter, Acetylcholine. Its distinct quaternary ammonium ion structure is significant because it prevents the molecule from crossing the blood-brain barrier, localizing its effects primarily to the peripheral nervous system. Unlike the natural compound, Bethanechol is structurally designed to resist rapid breakdown by cholinesterase, resulting in a more prolonged and therapeutically useful duration of action.

Forms, Composition, and General Purpose

Bethanechol is a single-ingredient product available in two primary dosage forms: tablets for oral intake and a sterile aqueous solution intended for subcutaneous injection. The core function of Bethanechol chloride is to directly bind to and stimulate the muscarinic receptors found on smooth muscles. This action serves to increase the muscle tone and contractility of the detrusor muscle of the bladder and the smooth muscles of the gastrointestinal tract. The primary therapeutic utility of cholinergic agonists like Bethanechol is in improving detrusor muscle contraction, which assists patients who experience difficulty initiating urination due to bladder muscle inactivity. Consequently, its general purpose is to restore the body's ability to effectively initiate voiding (micturition) and re-establish rhythmic intestinal movement (peristalsis) in cases where these functions have been compromised by a lack of muscle activity (atony).

What side effects are possible with Uriflow (Bethanechol)?

Possible Side Effects

As a cholinergic agent, Uriflow (Bethanechol) works by stimulating the body’s parasympathetic nervous system, which may cause side effects related to this activity. These effects are generally mild and often improve with continued use as the body adjusts to the medication. It is important to note that taking this medication on an empty stomach (either one hour before meals or two hours after) can help minimize gastrointestinal side effects such as nausea and vomiting.

Common Side Effects	Less Common or More Serious Side Effects (Seek medical attention)
Abdominal cramps or discomfort	Fainting or severe dizziness/lightheadedness
Nausea, vomiting, diarrhea	Slowed heart rate (bradycardia)
Increased salivation or tearing	Difficulty breathing, wheezing, or chest tightness
Flushing (warmth or redness of the skin)	Signs of an allergic reaction (hives, swelling of the face/throat)
Sweating	Severe abdominal pain
Headache, dizziness
Urinary urgency

Contraindications and Warnings

Bethanechol is contraindicated and should not be used in patients with certain pre-existing conditions due to the risk of serious complications. Always inform your healthcare provider of your complete medical history before starting treatment.

Do not take Uriflow if you have:

A known allergy or hypersensitivity to bethanechol.
Mechanical obstruction of the urinary or gastrointestinal tract.
Conditions where increased gastrointestinal or urinary tract activity could be harmful (e.g., recent bladder/intestinal surgery, weakened bladder wall).
Severe bradycardia (slow heart rate) or low blood pressure (hypotension).
Coronary artery disease (CAD).
Asthma or active bronchial asthma.
Hyperthyroidism (overactive thyroid gland).
Peptic ulcer.
Epilepsy or other seizure disorders.

Caution is also advised in pregnant or breastfeeding women, and use should only occur when clearly necessary after evaluating the potential risks and benefits.

Overdose and Emergency Response

Official Overdose Manifestations

Overdosage with Uriflow (Bethanechol) is an acute, dose-dependent exaggeration of the drug's intended action. Early signs documented in regulatory prescribing information typically include abdominal discomfort, salivation, flushing of the skin (a "hot feeling"), sweating, nausea, and vomiting. Larger, toxic doses may extend these effects to include colicky pain, diarrhea, abdominal cramps, and borborygmi.

When Immediate Medical Help is Required

Immediate medical attention is required due to the potential for violent symptoms of cholinergic overstimulation that affect major physiological systems. Severe, life-threatening outcomes documented in regulatory labeling include a fall in blood pressure leading to circulatory collapse, severe bronchospasm, and cardiac arrest. Any symptom suggestive of overdosage, especially respiratory or cardiac changes, must trigger an urgent response.

Antidote and Emergency Management

Atropine sulfate is explicitly identified in regulatory documents as the specific antidote for Bethanechol toxicity, and it must be readily available during administration. In cases of severe toxic cardiovascular or bronchoconstrictor responses, the antidote is administered. Procedural instructions for overdose situations include the mandate to maintain artificial respiration until the antidote can be fully administered. A specific antidote dose, lower than the adult dose, is documented for children up to 12 years of age.

Therapeutic Uses of Uriflow (Bethanechol)

What Uriflow (Bethanechol) Treats: Main Uses and Benefits

Bethanechol supports patients experiencing symptoms related to organ-specific functional stress, relevant in contexts involving heightened systemic burden, often associated with the urinary system. The medicine is considered relevant in conditions characterized by periods of heightened symptoms.

Bethanechol is commonly used to help with acute, nonobstructive symptoms related to physical discomfort (urinary retention), a symptom cluster that may become intense or disruptive and interferes with complete bladder emptying. Common scenarios where this occurs include symptoms associated with acute or episodic changes following a procedure, symptoms that become more disruptive during flare-ups related to systemic imbalance after childbirth, and symptoms of increased neurological or muscular activity linked to organ-specific functional stress.

By affecting specific physiological receptors, bethanechol assists in improving the stability of bladder function. This contributes to easing the overall symptom load by supporting the patient during difficult episodes. Certain clinical contexts suggest that Bethanechol is commonly used to help with nonobstructive urinary retention after specific procedures or childbirth. This may assist with maintaining functional stability during periods of heightened discomfort.

Quick Fact: Assists with symptoms that interfere with daily functioning

Regulatory References

NIH StatPearls overview

Eligibility and Restrictions for Use

Official Eligibility for Uriflow (Bethanechol)

Official regulatory documents define strict criteria for who can and cannot use Bethanechol. The medicine is primarily intended for adults experiencing acute postoperative or postpartum nonobstructive urinary retention. Use is generally confined to adult populations, as its safety and effectiveness have not been established in pediatric patients.

Contraindicated Populations (Must Not Use)

Bethanechol is absolutely contraindicated in patients with a wide range of pre-existing conditions, as its action can worsen these states. These contraindications define non-eligibility:

Mechanical Obstruction: Patients with a physical blockage of the urinary or gastrointestinal (GI) tract.
Cardiovascular Conditions: Patients with pronounced bradycardia, hypotension, coronary artery disease, or vasomotor instability.
GI/Pulmonary Conditions: Patients with a peptic ulcer or active or latent bronchial asthma.
Neurological/Endocrine: Patients with epilepsy, Parkinsonism, or hyperthyroidism.
Procedural Status: Patients who have recently undergone surgery on the bladder or intestines.

Conditional and Restricted Use

For pregnant patients, use is restricted to situations where the potential benefit justifies the potential risk. For lactating patients, use is generally not recommended due to the potential for adverse effects on the infant.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Uriflow (Bethanechol) is primarily structured around pharmacodynamic interactions, which reflect the potential for additive or antagonistic effects with other substances based on the body's nervous system responses. As the drug’s metabolic rate and mode of excretion are not fully elucidated in the official labeling, no specific enzyme-mediated (CYP) or transporter-mediated pharmacokinetic interactions are formally documented. This means the chief constraints relate to concurrent physiological effects.

Documented Interaction Constraints

Interaction Type	Interacting Agent	Official Regulatory Statement
Severe Pharmacodynamic Risk	Ganglion Blocking Compounds	Special care is required due to the documented potential for a critical fall in blood pressure when co-administered.
Additive Effects	Other Cholinergic Drugs	Concurrent use carries the potential for additive cholinergic effects.
Antagonistic Effects	Quinidine, Procainamide	These substances may antagonize the therapeutic effects of bethanechol.

Administration-Timing Requirement

Oral tablets must be separated from food ingestion as a procedural constraint. To manage potential gastrointestinal effects, tablets should be preferably taken one hour before or two hours after meals. No specific formal interactions are documented with alcohol, herbal products, or supplements in the official prescribing information.

Mechanism of Action

Bethanechol, a synthetic choline ester, functions as a direct-acting parasympathomimetic agent. Its mechanism involves selective agonism of muscarinic cholinergic receptors, primarily the M3 subtype.

These receptors are predominantly located on the smooth muscle cells of the detrusor muscle within the bladder wall. Activation of the M3 receptor triggers a downstream signaling cascade coupled via the Gq protein pathway. This cascade leads to an increase in the concentration of inositol triphosphate ( IP3) and the subsequent release of calcium ions ( Ca^2+) from the sarcoplasmic reticulum into the cytoplasm. The resulting rise in intracellular calcium stimulates the detrusor muscle to contract. This increase in muscle tone elevates intravesical pressure. Bethanechol's action is specific to muscarinic receptors and exhibits negligible activity at nicotinic receptors. The resulting muscle contraction represents a modulation of the cholinergic nervous system.

Dosage and Administration Information

Administration Method

Uriflow is typically administered as an oral tablet. For optimal absorption, it is generally recommended to take the medication on an empty stomach. Taking the tablet either one hour before a meal or two hours after a meal helps to minimize the potential for gastrointestinal side effects such as nausea or vomiting.

Consistency in Routine

Maintaining a regular schedule helps ensure a steady level of the medication remains in the system. Most individuals find it helpful to take their doses at the same times each day to establish a routine. If a dose is missed, it is common practice to resume the schedule with the next scheduled dose rather than taking multiple doses at once.

Storage and Handling

The medication should be stored at room temperature in a dry location, away from direct light and moisture. It is important to keep the container tightly closed when not in use and to ensure the medication is kept out of the reach of children and pets. Proper disposal of expired or unused medication is recommended according to local guidelines.

Recent Clinical Evidence

Research evidence / Overview of Studies for Uriflow (Bethanechol)

Evidence for Use in Acute Non-Obstructive Urinary Retention

Research has been studied for Bethanechol in the context of temporary, acute difficulty with urination, such as periods following surgery (post-operative) or after childbirth (post-partum). The available research includes short-term Randomized Controlled Trials (RCTs) and various observational studies. These studies primarily focused on adult patients and monitored outcomes related to functional changes over a very limited time frame.

Researchers monitored factors like the time it took for a patient to initiate voiding and changes in the amount of urine remaining (Post-Void Residual Urine, PVRU). Some findings describe patterns observed in the studies related to a reduced need for urinary catheterization in specific, short-term post-procedure settings. However, sample sizes were modest in many of these studies, and results regarding the consistency of PVRU volume changes were observed in some studies to be mixed.

The available evidence is considered to have moderate certainty regarding the outcomes measured in the acute settings studied. The follow-up durations were limited, meaning the research provides little insight into outcomes beyond the immediate, acute phase.

Evidence for Use in Neurogenic Bladder Atony

Bethanechol was studied for cases of bladder muscle weakness (atony) linked to nerve dysfunction (neurogenic bladder). The research consists primarily of specialized Urodynamic Studies and various clinical reports on specific groups of adults with defined nerve injuries.

Studies explored how the medicine might affect the bladder muscle's ability to contract. Reported responses in studies were highly variable and appeared dependent on the nature and severity of the underlying neurological condition. The research provides insight into acute physiological response, but data for long-term clinical outcomes remain limited.

Due to the age, size, and non-comparative nature of the research, the evidence certainty across all forms of neurogenic bladder is characterized by limited studies.

Studies in Chronic Residual Urine Volume (Detrusor Underactivity)

Research has been studied for Bethanechol's role in the management of persistent, chronic incomplete bladder emptying without obstruction. Several small-scale Randomized Controlled Trials (RCTs) reported findings showing no significant difference in key functional outcomes (such as PVRU or voided volume) when compared against a placebo. This indicates that the findings were mixed when evaluating changes in chronic emptying difficulties.

Long-Term Outcomes and Follow-up Studies

Most research focused on short-term symptom changes. Data for long-term outcomes are not well-characterized, and there is limited information regarding the persistence of observed patterns or the availability of long-term maintenance treatment data.

The Evidence Landscape: Key Limitations and Research Gaps

Overall, the research base for Bethanechol is characterized by several consistent limitations. Key limitations include the relative age and modest sample sizes of many pivotal studies, meaning results apply only to the populations studied. Data for certain groups, such as children, adolescents, or patients with specific comorbid conditions, remain insufficient.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Uriflow (Bethanechol) (FAQ)

Q: How quickly should I expect to notice any effects after starting Uriflow?

According to official product information, the effects of the oral tablet form of Uriflow generally begin within 30 to 90 minutes after the medicine is administered. The effects are often relatively short-lived, with the therapeutic action of a typical oral dose usually persisting for approximately one hour.

Q: Is Uriflow (Bethanechol) the same kind of drug as Flomax (tamsulosin)?

No. Official classifications show that Uriflow (bethanechol) is a cholinergic muscarinic agonist, which means it works by actively stimulating certain muscles to contract. Drugs like Flomax (tamsulosin), in contrast, are classified as alpha-blockers, which work by relaxing muscles in different parts of the urinary system. These agents belong to different pharmacological drug classes.

Q: What is the difference between Uriflow and other drugs used for urinary retention?

Uriflow is a direct-acting parasympathomimetic agent (a type of cholinergic agonist). Its main function is to stimulate the detrusor muscle in the bladder to contract, helping to improve muscle tone. This mechanism is distinct from other classes of drugs, such as alpha-blockers, which affect the relaxation of surrounding tissues rather than the contraction of the bladder muscle itself.

Q: Is Uriflow (Bethanechol) safe to take if I also take a blood pressure medicine?

Official labeling contains a warning that special care is required if Uriflow is administered alongside ganglion blocking compounds due to the potential for a critical fall in blood pressure. Official labeling notes that people using blood pressure medication may require specific guidance.

Q: Does Uriflow (Bethanechol) interact with common supplements like vitamins or herbal remedies?

Official regulatory labeling does not formally document any specific interactions between Uriflow and most common supplements or herbal products. This means that no specific safety claim or guidance for prohibition regarding their combination is listed in the official prescribing information.

Q: Is Uriflow (Bethanechol) used for conditions other than just urinary problems?

The primary therapeutic purpose listed in the official prescribing information is the treatment of non-obstructive urinary retention. The drug's mechanism of action also involves stimulating smooth muscles of the gastrointestinal tract (affecting peristalsis), but its official therapeutic purpose is defined as the treatment of urinary retention.

Q: Is Uriflow (Bethanechol) available under other brand names?

Yes, the active ingredient bethanechol chloride is associated with other brand names in certain global markets. Examples of other brand names include Urecholine and Duvoid.

Q: Is Uriflow (Bethanechol) considered safe during pregnancy or breastfeeding according to official sources?

Official regulatory documents recommend that the drug be used during pregnancy only when it is considered clearly needed and when the potential benefit is believed to outweigh the potential risk. Additionally, use while breastfeeding is generally not recommended due to limited data on its excretion into breast milk and the potential for adverse effects on the infant.

Q: Can Uriflow (Bethanechol) affect sleep patterns?

Some official summaries of adverse events list nervousness, jitters, or sleeplessness as possible reactions, which could potentially impact sleep patterns. It is important to observe for any changes that may occur.

Q: Are the side effects of Uriflow (Bethanechol) dose-dependent?

Yes, official labeling indicates a relationship between the amount taken and the likelihood of effects. Large doses more commonly result in pronounced signs of parasympathetic stimulation, which can include effects like flushing, colicky pain, diarrhea, and a fall in blood pressure.

Q: Does the evidence for Uriflow (Bethanechol) come from large-scale clinical trials?

Research overviews indicate that the evidence base for Uriflow is characterized by relatively old studies and reports that generally involve modest-sized groups. This evidence base is characterized by trials and reports that generally involve modest-sized groups, rather than large-scale, modern clinical trials.

Q: Can Uriflow (Bethanechol) affect mental clarity or focus?

Dizziness, lightheadedness, and headache are listed as common side effects in the prescribing information. Furthermore, official patient caution documents note that the drug may potentially affect coordination, reaction time, or judgment.

Q: Why is Uriflow (Bethanechol) sometimes given by injection in a clinical setting?

The injectable form is restricted to subcutaneous use in a clinical setting. This route is primarily used in clinical settings because the effects of the injection may appear more rapidly compared to the oral form, which can be relevant in acute clinical situations.

Q: Does taking Uriflow (Bethanechol) require any specific changes to diet or fluid intake?

The primary requirement involves timing: the tablets must be taken on an empty stomach—specifically one hour before or two hours after meals. This constraint is intended to reduce the potential for gastrointestinal side effects like nausea and vomiting. The official labels do not mandate any specific changes to general diet or fluid consumption beyond the required timing relative to meals.

Q: Can Uriflow (Bethanechol) interact with eye drops or nasal sprays?

Due to its mechanism, Uriflow has the potential to interact with other drugs that produce either similar (cholinergic) or opposing (anticholinergic) effects on the nervous system. Certain ophthalmic (eye) preparations and nasal sprays contain ingredients that fall into these categories, which can lead to possible combined effects.

Q: Are there any restrictions on activity or exercise while using Uriflow (Bethanechol)?

Official patient caution documents note the potential for side effects like dizziness, lightheadedness, or fainting. Activities requiring attention, such as driving or operating machinery, may be restricted until the patient knows how the medicine affects them.

Q: What happens if a dose of Uriflow (Bethanechol) is missed?

Regulatory patient information often describes procedures for missed doses. This guidance typically suggests that a missed dose should be skipped if too much time has passed, and that patients should return to their regular schedule, avoiding attempts to double the dose.

Q: How long does Uriflow (Bethanechol) typically stay in the system?

While the drug's half-life (the time it takes for half of the dose to be cleared) is not fully defined in all labels, the therapeutic effect of a typical oral dose is described as persisting for approximately one hour. The overall physiological effects of larger doses may continue for up to six hours.

How should Uriflow (Bethanechol) be stored and disposed of?

Official Storage and Disposal Requirements

The following storage and disposal requirements are based on authoritative governmental regulatory documents, such as those from the NIH/MedlinePlus and the FDA.

Storage Constraints

Requirement	Details
Temperature	Store at room temperature.
Protection	Protect from excess heat and moisture.
Packaging	Keep the medicine in its original container, tightly closed.
Child Safety	Keep out of sight and reach of children in a secure location.

Disposal Protocol

Bethanechol is not on the official FDA Flush List. The recommended disposal method is to use a community drug take-back program. If this is unavailable, the medication must be mixed with an unappealing substance, like dirt or used coffee grounds, sealed in a bag or container, and discarded in the household trash. The empty drug packaging should have all personal information scratched out.

Uriflow (Bethanechol)